Compare HUMA & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HUMA | ACHV |
|---|---|---|
| Founded | 2004 | N/A |
| Country | United States | United States |
| Employees | 184 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.4M | 172.0M |
| IPO Year | N/A | 2018 |
| Metric | HUMA | ACHV |
|---|---|---|
| Price | $0.71 | $4.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 3 |
| Target Price | $6.19 | ★ $14.67 |
| AVG Volume (30 Days) | ★ 5.7M | 1.6M |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $444.16 | N/A |
| Revenue Next Year | $248.39 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.55 | $2.00 |
| 52 Week High | $2.93 | $6.03 |
| Indicator | HUMA | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 45.53 | 52.21 |
| Support Level | $0.55 | $2.59 |
| Resistance Level | $1.27 | $4.98 |
| Average True Range (ATR) | 0.06 | 0.39 |
| MACD | 0.02 | 0.09 |
| Stochastic Oscillator | 67.38 | 42.08 |
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.